Bausch Health Companies Inc.’s (BHC) global eye health business Bausch + Lomb and Clearside Biomedical, Inc. (CLSD) have bagged the U.S. Food and Drug Administration’s (FDA) approval for XIPERE, which is designed to treat macular edema associated with uveitis via suprachoroidal administration. Following the news, shares of Bausch Health gained 2.7% in early trade on Monday. Meanwhile, shares of Clearside declined 4.6%. The approval is based on the pivotal Phase 3 trial (PEACHTREE), a Phase 3, multi-center, non-interventional extension study (MAGNOLIA), and an open-label safety trial (AZALEA).
https://www.tipranks.com/news/bausch-lomb-clearside-bag-fda-approval-for-xipere?utm_source=advfn.com&utm_medium=referral
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Oct 2021 to Nov 2021 Click Here for more Clearside Biomedical Charts.
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Nov 2020 to Nov 2021 Click Here for more Clearside Biomedical Charts.